For decades, menopause was treated as something women were expected to endure in silence — a passage, not a condition. Now, with clinical guidelines rewritten and cultural stigma softening, hormone replacement therapy use has nearly doubled since 2017, most visibly among women in their late 40s and early 50s. The shift reflects not just a change in medicine, but a change in who gets to be heard: women naming their suffering, and a medical establishment finally updating its answers.
Hormone therapy for menopause surges: What women need to know
Cobertura Relacionada
A rare solar eclipse across the UK and Europe captures headlines with dramatic imagery and public celebration, while new…
The New York Times · Aug 13 Total Eclipse Sweeps Across Europe From Iceland to SpainA total solar eclipse crossed Europe from Iceland to Spain, drawing crowds to viewing locations as the moon completely b…
Times of India · Aug 13 Total solar eclipse returns to Spain after 121 years, mesmerizes EuropeA total solar eclipse crossed Spain and Iceland on Wednesday, marking Western Europe's first since 1999 and Spain's firs…
e-flux.com · Aug 13 M-Cult announces 2026–27 artist residencies with open call for Nordic-Baltic creatorsM-Cult opens residency programs in Helsinki with selected international artists exploring urban nature and technology, p…
Sesgo y Encuadre
Article presents hormone therapy surge neutrally with clinical framing, though lacks discussion of risks, long-term effects, and dissenting medical perspectives.
Medical authority framing: relies heavily on updated clinical guidelines and expert sources (NPR, Norton Healthcare, Medscape) to legitimize hormone therapy adoption without proportional emphasis on contraindications or alternative approaches.
Impacto Geopolítico
This article concerns domestic healthcare policy on hormone replacement therapy and has no geopolitical implications.
Lente Económico
Hormone replacement therapy use has nearly doubled since 2017, driven by updated clinical guidelines, creating significant growth opportunities in pharmaceuticals and healthcare services for menopausal women.
Women aged 40-55 face increased healthcare costs for HRT treatments and related medical consultations, though improved quality of life may offset expenses. Increased demand may improve access to menopause care but could strain healthcare provider capacity.
Regulatory bodies may review HRT safety protocols and efficacy standards. Insurance coverage policies may expand to accommodate increased demand. Healthcare systems may need to allocate more resources to gynecological and endocrinological services. Potential for increased FDA scrutiny of hormone therapy products.